LMDX LUMIRADX LTD

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

On January 27, 2023, Nasdaq notified the Company that its common shares had failed to maintain a minimum bid price of US$1.00 over the previous 30 consecutive trading days as required by the Listing Rules of The Nasdaq Stock Market. On February 17, 2023, Nasdaq notified the Company that for 11 consecutive business days, from February 2 to February 16, 2023, the closing bid price of the Company’s common shares has been above US$1.00 per share. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) and Nasdaq has deemed this matter closed.

About LumiraDx

LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.

The Company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The Company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.

Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease. More information on LumiraDx is available at .



EN
17/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LUMIRADX LTD

 PRESS RELEASE

LumiraDx Announces its Securities will be Suspended from Trading on Na...

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company’s failure to maintain compliance with Nasdaq’s continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq’s Listing Qu...

 PRESS RELEASE

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Te...

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx’s innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulti...

 PRESS RELEASE

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to...

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bi...

 PRESS RELEASE

LumiraDx Partners with AstraZeneca & Everton in the Community to Set U...

LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club – Everton in the Community – the Liverpool-based hub will provide significant support for individuals suffering from chronic breathlessness and other heart and lung-related conditions in a community-based setting.The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample.Run on the LumiraDx...

 PRESS RELEASE

LumiraDx to Announce Second Quarter Financial Results and Host Quarter...

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24 LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch